Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots
6 May 2021
Andrew Pollard writes about vaccine equity in his article for The Conversation.
Increasing vaccine uptake among ethnic minorities
6 May 2021
COVID-19 Public Engagement Vaccinology
Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.
Why we must expand newborn screening
6 May 2021
Neuromuscular Diseases Research
Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.
Human challenge trial launches to study immune response to COVID-19
20 April 2021
Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
Alternating vaccines trial expands to include two additional vaccines
14 April 2021
COVID-19 Clinical Trials Vaccinology
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
UK and EU regulators conclude benefits of vaccination continue to outweigh the risks
7 April 2021
Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
Oxford University researchers release cheap, quick COVID-19 antibody test
31 March 2021
The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.
AstraZeneca publish primary analysis from US trial of coronavirus vaccine
25 March 2021
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective
22 March 2021
- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall - Vaccine 100% effective against severe or critical symptomatic COVID-19 - No safety concerns reported
Innovation award for Paediatrics researcher to develop new treatments for childhood cancer
18 March 2021
Awards & Appointments Haematology
Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.
Celebrating Early Careers Researchers on International Women's Day
8 March 2021
In these short interviews, Anna Kordala and Jane Millar talk about the research they do at the Department of Paediatrics.
Professor Matthew Snape named NIHR Senior Investigator
4 March 2021
Awards & Appointments Vaccinology
Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.
Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests
24 February 2021
The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
Oxford University extends COVID-19 vaccine study to children
13 February 2021
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
World Health Organization experts provide guidance on use of the Oxford vaccine
11 February 2021
WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.
Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK
5 February 2021
A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.
Oxford leads first trial investigating dosing with alternating vaccines
4 February 2021
COVID-19 Clinical Trials Vaccinology
The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium
26 January 2021
Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
Oxford University welcomes UK regulatory emergency use authorisation of coronavirus vaccine
30 December 2020
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
10 December 2020
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.